Abstract
Interim positron emission tomography (PET) -guided therapy and brentuximab vedotin (BV) combined systemic chemotherapy have been developed for newly diagnosed classical Hodgkin's lymphoma (cHL). A majority of recent trials using interim PET response-adapted approaches have assessed the treatment strategies for cHL and reported that the initial treatment could be suitably altered to intensive treatment in an early phase, thereby enhancing the efficacy in interim PET-positive patients, whereas the simplified treatment regimen, such as omitting drugs or radiation, could minimize the risk of toxicity in interim PET-negative patients. This review includes the current evidence primarily focusing on randomized clinical trials including patients with newly diagnosed cHL to investigate the efficacy and safety of interim PET-guided therapy or BV combined regimen and also mentions that issues.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
